Belgium
Hippo Dx is a MedTech start-up founded in 2020, specializing in allergy testing and diagnosis. The company's innovative medical device, S.P.A.T. (Skin Prick Automated Test), revolutionizes allergy testing by automating the skin prick test, significantly reducing result variability and time consumption. S.P.A.T. conducts 12 pricks concurrently in just 20 seconds, providing standardized digital results in 15 minutes, allowing for seamless record-keeping and enhanced efficiency.
This breakthrough technology not only streamlines the testing process but also alleviates the workload for healthcare professionals, emphasizing patient care. Moreover, the digital processing and storage of test results contribute to a more comprehensive understanding of allergies with deep scientific insights. This in turn paves the way for global advancements in allergy research and treatment.
The company operates at the intersection of Health Care and Manufacturing industries, aiming to redefine the standard for allergy testing. Although there is no disclosed information about the last investment or investors, the potential for S.P.A.T. to revolutionize allergy diagnostics and treatment makes Hippo Dx a compelling venture for potential investors seeking to drive innovation in healthcare.
To learn more about S.P.A.T. and its potential impact, visit www.hippo-dx.com.
